BofA upgrades Moderna to Neutral after 177% surge tied to personalized cancer-vaccine data

Moderna’s shares jumped sharply, and a Wall Street firm has responded with a fresh view of the outlook. Bank of America upgraded Moderna to a Neutral rating and assigned a $170 price objective after the stock rallied about 177% following reported positive data connected to the company’s personalized cancer vaccine, intismeran, in adjuvant melanoma.

The update comes in the wake of the market repricing Moderna on heightened expectations for oncology progress. According to the report, the catalyst was positive data tied to intismeran, a personalized vaccine designed to be tailored to an individual patient’s tumor profile. The adjuvant setting, meaning after initial treatment to help reduce recurrence risk, is typically viewed by investors as an area where durable benefit matters.

Bank of America’s shift to Neutral suggests the firm sees the breakthrough announcement as meaningful, but not enough on its own to justify an outright bullish rating at this stage. A Neutral stance usually indicates analysts expect shares to perform in line with broader markets rather than materially outperform, despite potential catalysts.

The bank’s $170 target provides one benchmark for how it is balancing upside from oncology developments against risks that often accompany early or mid-stage clinical readouts. Even when data are described as positive, investors and analysts typically need additional follow-up, durability of response, confirmation across endpoints, and clarity on the path to broader use before a more aggressive rating is warranted.

Moderna has built its business around mRNA (messenger RNA) technology, which uses genetic instructions delivered into the body to prompt cells to produce targeted proteins. In vaccines, the approach is designed to help the immune system recognize specific disease-related targets. In cancer, personalized vaccines aim to direct immune responses toward tumor features associated with a patient’s cancer, rather than relying on a one-size-fits-all antigen.

While the report centers on intismeran and adjuvant melanoma, it does not provide, in the information available here, the specific clinical endpoints, sample size details, or the magnitude of effect. It also does not state whether the results were from a phase of development that would typically be seen as late-stage confirmation versus earlier-stage evidence. Those details can matter to how aggressively the market prices in probability-weighted outcomes.

The firm’s reaction also underscores a broader pattern in healthcare markets: oncology readouts, even when confined to a specific indication, can rapidly swing expectations for platform companies. After a surge like 177%, sell-side firms often reframe probability assumptions rather than ignore the data entirely, which may explain the move to Neutral rather than a continued prior stance or a more dramatic upgrade.

For investors and stakeholders, the next watch items are not spelled out in the report, and that gap is important. What to look for next would generally include updated clinical figures, longer follow-up to assess durability, and any disclosures about manufacturing timeline, scalability, and how the company plans to integrate personalized treatment into clinical workflows. Without that additional detail, the extent to which intismeran can translate into a sustained commercial pathway remains uncertain.